Pulmonary Amyloidosis

Abstract

Amyloidosis is a heterogeneous group of rare diseases characterized by the deposition of misfolded and insoluble proteins in tissues. Lung involvement, airways or parenchyma, is relatively common, but usually mild. Some patients may develop chronic progressive forms or experience life-threatening complications. In this review, we summarize the most recent advances in the comprehension of molecular mechanisms and classification of amyloidosis. We then illustrate the different forms of lung amyloidosis and the current treatment options. Increased awareness in the medical community and the creation of referral centers' networks are of paramount importance to ensure adequate management and access to treatment.

Keywords

amyloidosis - amyloid fibrils - lung - airways - amyloidomas - rare lung disease

Publikationsverlauf

Eingereicht: 10. Juli 2025

Angenommen: 16. September 2025

Artikel online veröffentlicht:
14. Oktober 2025

• References

• 1 Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003; 349 (06) 583-596
• 2 Buxbaum JN, Eisenberg DS, Fändrich M. et al. Amyloid nomenclature 2024: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee. Amyloid 2024; 31 (04) 249-256
• 3 Buxbaum JN, Dispenzieri A, Eisenberg DS. et al. Amyloid nomenclature 2022: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee. Amyloid 2022; 29 (04) 213-219
• 4 Milani P, Basset M, Russo F, Foli A, Palladini G, Merlini G. The lung in amyloidosis. Eur Respir Rev 2017; 26 (145) 170046
• 5 Baqir M, Roden AC, Moua T. Amyloid in the Lung. Semin Respir Crit Care Med 2020; 41 (02) 299-310
• 6 Riehani A, Soubani AO. The spectrum of pulmonary amyloidosis. Respir Med 2023; 218: 107407
• 7 Benson MD, Buxbaum JN, Eisenberg DS. et al. Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid 2018; 25 (04) 215-219
• 8 Simms RW, Prout MN, Cohen AS. The epidemiology of AL and AA amyloidosis. Baillieres Clin Rheumatol 1994; 8 (03) 627-634
• 9 Ravichandran S, Lachmann HJ, Wechalekar AD. Epidemiologic and survival trends in amyloidosis, 1987-2019. N Engl J Med 2020; 382 (16) 1567-1568
• 10 Waddington-Cruz M, Schmidt H, Botteman MF. et al. Epidemiological and clinical characteristics of symptomatic hereditary transthyretin amyloid polyneuropathy: A global case series. Orphanet J Rare Dis 2019; 14 (01) 34
• 11 Kyle RA, Linos A, Beard CM. et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood 1992; 79 (07) 1817-1822
• 12 Pinney JH, Smith CJ, Taube JB. et al. Systemic amyloidosis in England: An epidemiological study. Br J Haematol 2013; 161 (04) 525-532
• 13 Quock TP, Yan T, Chang E, Guthrie S, Broder MS. Epidemiology of AL amyloidosis: A real-world study using US claims data. Blood Adv 2018; 2 (10) 1046-1053
• 14 Kyle RA, Larson DR, Kurtin PJ. et al. Incidence of AL amyloidosis in Olmsted County, Minnesota, 1990 through 2015. Mayo Clin Proc 2019; 94 (03) 465-471
• 15 Porcari A, Merlo M, Rapezzi C, Sinagra G. Transthyretin amyloid cardiomyopathy: An uncharted territory awaiting discovery. Eur J Intern Med 2020; 82: 7-15
• 16 Berk JL, O'Regan A, Skinner M. Pulmonary and tracheobronchial amyloidosis. Semin Respir Crit Care Med 2002; 23 (02) 155-165
• 17 Kato-Motozaki Y, Ono K, Shima K. et al. Epidemiology of familial amyloid polyneuropathy in Japan: Identification of a novel endemic focus. J Neurol Sci 2008; 270 (1-2): 133-140
• 18 Inês M, Coelho T, Conceição I, Duarte-Ramos F, de Carvalho M, Costa J. Epidemiology of transthyretin familial amyloid polyneuropathy in Portugal: A nationwide study. Neuroepidemiology 2018; 51 (3-4): 177-182
• 19 Jacobson DR, Alexander AA, Tagoe C. et al. The prevalence and distribution of the amyloidogenic transthyretin (TTR) V122I allele in Africa. Mol Genet Genomic Med 2016; 4 (05) 548-556
• 20 Parman Y, Adams D, Obici L. et al; European Network for TTR-FAP (ATTReuNET). Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP. Curr Opin Neurol 2016; 29(Suppl 1) (Suppl. 01) S3-S13
• 21 Cohen AS, Calkins E. Electron microscopic observations on a fibrous component in amyloid of diverse origins. Nature 1959; 183 (4669): 1202-1203
• 22 Eanes ED, Glenner GG. X-ray diffraction studies on amyloid filaments. J Histochem Cytochem 1968; 16 (11) 673-677
• 23 Iadanza MG, Jackson MP, Hewitt EW, Ranson NA, Radford SE. A new era for understanding amyloid structures and disease. Nat Rev Mol Cell Biol 2018; 19 (12) 755-773
• 24 Chiti F, Dobson CM. Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem 2006; 75: 333-366
• 25 Riek R, Eisenberg DS. The activities of amyloids from a structural perspective. Nature 2016; 539 (7628): 227-235
• 26 Blake C, Serpell L. Synchrotron X-ray studies suggest that the core of the transthyretin amyloid fibril is a continuous β-sheet helix. Structure 1996; 4 (08) 989-998
• 27 Tennent GA, Lovat LB, Pepys MB. Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proc Natl Acad Sci U S A 1995; 92 (10) 4299-4303
• 28 Pepys MB. Immunotherapeutic clearance of systemic amyloid deposits by antibodies to serum amyloid P component. Amyloid 2017; 24 (sup1): 5-6
• 29 Bochtler T, Hegenbart U, Heiss C. et al. Hyperdiploidy is less frequent in AL amyloidosis compared with monoclonal gammopathy of undetermined significance and inversely associated with translocation t(11;14). Blood 2011; 117 (14) 3809-3815
• 30 Morgan GJ, Kelly JW. The kinetic stability of a full-length antibody light chain dimer determines whether endoproteolysis can release amyloidogenic variable domains. J Mol Biol 2016; 428 (21) 4280-4297
• 31 Morgan GJ, Wall JS. The process of amyloid formation due to monoclonal immunoglobulins. Hematol Oncol Clin North Am 2020; 34 (06) 1041-1054
• 32 Westermark GT, Fändrich M, Lundmark K, Westermark P. Noncerebral amyloidoses: Aspects on seeding, cross-seeding, and transmission. Cold Spring Harb Perspect Med 2018; 8 (01) a024323
• 33 Merlini G, Dispenzieri A, Sanchorawala V. et al. Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Primers 2018; 4 (01) 38
• 34 Desikan KR, Dhodapkar MV, Hough A. et al. Incidence and impact of light chain associated (AL) amyloidosis on the prognosis of patients with multiple myeloma treated with autologous transplantation. Leuk Lymphoma 1997; 27 (3-4): 315-319
• 35 Kyle RA, Larson DR, Therneau TM. et al. Long-term follow-up of monoclonal gammopathies of undetermined significance. N Engl J Med 2018; 378 (03) 241-249
• 36 Kyle RA, Therneau TM, Rajkumar SV. et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006; 354 (13) 1362-1369
• 37 Sanchorawala V. Systemic light chain amyloidosis. N Engl J Med 2024; 390 (24) 2295-2307
• 38 Koss MN, Hochholzer L, Moran CA, Frizzera G. Pulmonary plasmacytomas: a clinicopathologic and immunohistochemical study of five cases. Ann Diagn Pathol 1998; 2 (01) 1-11
• 39 Piard F, Yaziji N, Jarry O. et al. Solitary plasmacytoma of the lung with light chain extracellular deposits: A case report and review of the literature. Histopathology 1998; 32 (04) 356-361
• 40 Madan S, Dispenzieri A, Lacy MQ. et al. Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma. Mayo Clin Proc 2010; 85 (03) 232-238
• 41 Kyle RA, Gertz MA. Primary systemic amyloidosis: Clinical and laboratory features in 474 cases. Semin Hematol 1995; 32 (01) 45-59
• 42 Jeong YJ, Lee KS, Chung MP. et al. Amyloidosis and lymphoproliferative disease in Sjögren syndrome: Thin-section computed tomography findings and histopathologic comparisons. J Comput Assist Tomogr 2004; 28 (06) 776-781
• 43 Delèvaux I, André M, Amoura Z, Kémény JL, Piette JC, Aumaître O. Concomitant diagnosis of primary Sjögren's syndrome and systemic AL amyloidosis. Ann Rheum Dis 2001; 60 (07) 694-695
• 44 Rajagopala S, Singh N, Gupta K, Gupta D. Pulmonary amyloidosis in Sjogren's syndrome: A case report and systematic review of the literature. Respirology 2010; 15 (05) 860-866
• 45 Yamada T. Serum amyloid A (SAA): A concise review of biology, assay methods and clinical usefulness. Clin Chem Lab Med 1999; 37 (04) 381-388
• 46 Lane T, Pinney JH, Gilbertson JA. et al. Changing epidemiology of AA amyloidosis: clinical observations over 25 years at a single national referral centre. Amyloid 2017; 24 (03) 162-166
• 47 Myllykangas-Luosujärvi R, Aho K, Kautiainen H, Hakala M. Amyloidosis in a nationwide series of 1666 subjects with rheumatoid arthritis who died during 1989 in Finland. Rheumatology (Oxford) 1999; 38 (06) 499-503
• 48 Dasari S, Theis JD, Vrana JA. et al. Amyloid typing by mass spectrometry in clinical practice: A comprehensive review of 16,175 samples. Mayo Clin Proc 2020; 95 (09) 1852-1864
• 49 De Beer FC, Mallya RK, Fagan EA, Lanham JG, Hughes GR, Pepys MB. Serum amyloid-A protein concentration in inflammatory diseases and its relationship to the incidence of reactive systemic amyloidosis. Lancet 1982; 2 (8292): 231-234
• 50 Mirioglu S, Uludag O, Hurdogan O. et al. AA amyloidosis: A contemporary view. Curr Rheumatol Rep 2024; 26 (07) 248-259
• 51 Papa R, Lachmann HJ. Secondary, AA, amyloidosis. Rheum Dis Clin North Am 2018; 44 (04) 585-603
• 52 Brunger AF, Nienhuis HLA, Bijzet J, Hazenberg BPC. Causes of AA amyloidosis: A systematic review. Amyloid 2020; 27 (01) 1-12
• 53 Smith RRL, Hutchins GM, Moore GW, Humphrey RL. Type and distribution of pulmonary parenchymal and vascular amyloid. Correlation with cardiac amyloid. Am J Med 1979; 66 (01) 96-104
• 54 Lachmann HJ, Hawkins PN. Amyloidosis and the lung. Chron Respir Dis 2006; 3 (04) 203-214
• 55 Sikora J, Kmochová T, Mušálková D. et al. A mutation in the SAA1 promoter causes hereditary amyloid A amyloidosis. Kidney Int 2022; 101 (02) 349-359
• 56 Bunker D, Gorevic P. AA amyloidosis: Mount Sinai experience, 1997-2012. Mt Sinai J Med 2012; 79 (06) 749-756
• 57 Palladini G, Riva E, Basset M. et al. Prognostication of survival and progression to dialysis in AA amyloidosis. Amyloid 2017; 24 (sup1): 136-137
• 58 Baumgart JV, Stuhlmann-Laeisz C, Hegenbart U. et al. Local vs. systemic pulmonary amyloidosis-impact on diagnostics and clinical management. Virchows Arch 2018; 473 (05) 627-637
• 59 Motosugi U, Ichikawa T, Araki T, Endo S, Masuyama K, Nakazawa T. Localized nasopharyngeal amyloidosis with remarkable early enhancement on dynamic contrast-enhanced MR imaging. Eur Radiol 2007; 17 (03) 852-853
• 60 Ollenberger GP, Knight S, Tauro AJ. False-positive FDG positron emission tomography in pulmonary amyloidosis. Clin Nucl Med 2004; 29 (10) 657-658
• 61 Tan H, Guan Y, Zhao J, Lin X. Findings of pulmonary amyloidosis on dual phase FDG PET/CT imaging. Clin Nucl Med 2010; 35 (03) 206-207
• 62 Soussan M, Ouvrier MJ, Pop G, Galas JL, Neuman A, Weinmann P. Tracheobronchial FDG uptake in primary amyloidosis detected by PET/CT. Clin Nucl Med 2011; 36 (08) 723-724
• 63 Howard S, Jagannathan J, Krajewski K. et al. Multimodality imaging in amyloidosis. Cancer Imaging 2012; 12 (01) 109-117
• 64 Baqir M, Lowe V, Yi ES, Ryu JH. ¹⁸F-FDG PET scanning in pulmonary amyloidosis. J Nucl Med 2014; 55 (04) 565-568
• 65 Cresner R, Mahmood S, Chen J, Rowan C, Wechalekar AD. Thoracic amyloidomas: Two case reports of an evasive diagnosis. JRSM Open 2014; 5 (06) 2054270414527280
• 66 Dong MJ, Zhao K, Liu ZF, Wang GL, Yang J. Primary pulmonary amyloidosis misdiagnosed as malignancy on dual-time-point fluoro-deoxyglucose positron emission tomography/computed tomography: A case report and review of the literature. Oncol Lett 2015; 9 (02) 591-594
• 67 Khor YM, Cuddy S, Harms HJ. et al. Quantitative [¹⁸F]florbetapir PET/CT may identify lung involvement in patients with systemic AL amyloidosis. Eur J Nucl Med Mol Imaging 2020; 47 (08) 1998-2009
• 68 Hawkins PN. Serum amyloid P component scintigraphy for diagnosis and monitoring amyloidosis. Curr Opin Nephrol Hypertens 2002; 11 (06) 649-655
• 69 Hawkins PN, Lavender JP, Pepys MB. Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N Engl J Med 1990; 323 (08) 508-513
• 70 Gillmore JD, Wechalekar A, Bird J. et al; BCSH Committee. Guidelines on the diagnosis and investigation of AL amyloidosis. Br J Haematol 2015; 168 (02) 207-218
• 71 Hazenberg BPC, van Rijswijk MH, Piers DA. et al. Diagnostic performance of 123I-labeled serum amyloid P component scintigraphy in patients with amyloidosis. Am J Med 2006; 119 (04) 355.e15-355.e24
• 72 Yakupova EI, Bobyleva LG, Vikhlyantsev IM, Bobylev AG. Congo Red and amyloids: history and relationship. Biosci Rep 2019; 39 (01) BSR20181415
• 73 Zanwar S, Gertz MA, Muchtar E. Immunoglobulin light chain amyloidosis: Diagnosis and risk assessment. J Natl Compr Canc Netw 2023; 21 (01) 83-90
• 74 Zamora AC, White DB, Sykes AMG. et al. Amyloid-associated cystic lung disease. Chest 2016; 149 (05) 1223-1233
• 75 Govender P, Keyes CM, Hankinson EA, O'Hara CJ, Sanchorawala V, Berk JL. Transbronchial biopsies safely diagnose amyloid lung disease. Amyloid 2017; 24 (01) 37-41
• 76 Gaultier S, Puscas T, Pastre J. et al. Transbronchial cryobiopsy proven amyloid diffuse cystic lung disease complicating a transthyretin mutated (ATTRm) amyloidosis: a case report. Ther Adv Respir Dis 2023; 17: 17 534666231178690
• 77 Fujimoto K, Inomata M, Ito Y. et al. Pulmonary amyloidosis diagnosed via transbronchial lung cryobiopsy without surgical lung biopsy: A case series. Respir Med Case Rep 2022; 38 (May): 101688
• 78 Mumford AD, O'Donnell J, Gillmore JD, Manning RA, Hawkins PN, Laffan M. Bleeding symptoms and coagulation abnormalities in 337 patients with AL-amyloidosis. Br J Haematol 2000; 110 (02) 454-460
• 79 Greipp PR, Kyle RA, Bowie EJW. Factor-X deficiency in amyloidosis: a critical review. Am J Hematol 1981; 11 (04) 443-450
• 80 Gertz MA, Kyle RA. Hepatic amyloidosis (primary [AL], immunoglobulin light chain): the natural history in 80 patients. Am J Med 1988; 85 (01) 73-80
• 81 Gillmore JD, Hawkins PN. Pathophysiology and treatment of systemic amyloidosis. Nat Rev Nephrol 2013; 9 (10) 574-586
• 82 Dejhansathit S, Suvannasankha A. Acquired factor X deficiency in patients with primary light chain amyloidosis. J Investig Med High Impact Case Rep 2019; 7: 2324709619832332
• 83 Ericson S, Shah N, Liberman J, Aboulafia DM. Fatal bleeding due to acquired factor IX and X deficiency: A rare complication of primary amyloidosis; case report and review of the literature. Clin Lymphoma Myeloma Leuk 2014; 14 (03) e81-e86
• 84 Thompson CA, Kyle R, Gertz M, Heit J, Pruthi R, Pardanani A. Systemic AL amyloidosis with acquired factor X deficiency: A study of perioperative bleeding risk and treatment outcomes in 60 patients. Am J Hematol 2010; 85 (03) 171-173
• 85 Shah PL, Gillmore JD, Copley SJ. et al. The importance of complete screening for amyloid fibril type and systemic disease in patients with amyloidosis in the respiratory tract. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19 (02) 134-142
• 86 Schönland SO, Hegenbart U, Bochtler T. et al. Immunohistochemistry in the classification of systemic forms of amyloidosis: A systematic investigation of 117 patients. Blood 2012; 119 (02) 488-493
• 87 Giannini G, Nast CC. An organ system-based approach to differential diagnosis of amyloid type in surgical pathology. Arch Pathol Lab Med 2020; 144 (03) 379-387
• 88 Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen III HR, Dogan A. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood 2009; 114 (24) 4957-4959
• 89 Brambilla F, Lavatelli F, Di Silvestre D. et al. Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue. Blood 2012; 119 (08) 1844-1847
• 90 Fernández de Larrea C, Verga L, Morbini P. et al. A practical approach to the diagnosis of systemic amyloidoses. Blood 2015; 125 (14) 2239-2244
• 91 Agbor-Etang BB, Okafor HE, Farber-Eger EH, Wells QS. Low prevalence of clinically apparent cardiac amyloidosis among carriers of transthyretin V122I variant in a large electronic medical record. Am J Med 2021; 134 (02) e98-e100
• 92 Mahmood S, Bridoux F, Venner CP. et al. Natural history and outcomes in localised immunoglobulin light-chain amyloidosis: A long-term observational study. Lancet Haematol 2015; 2 (06) e241-e250
• 93 Palladini G, Russo P, Bosoni T. et al. Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. Clin Chem 2009; 55 (03) 499-504
• 94 Gertz MA, Comenzo R, Falk RH. et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005; 79 (04) 319-328
• 95 Zimna K, Sobiecka M, Langfort R, Błasińska K, Tomkowski WZ. Pulmonary amyloidosis mimicking interstitial lung disease and malignancy - A case series with a review of a pulmonary patterns. Respir Med Case Rep 2021; 33: 101427
• 96 Khoor A, Colby TV. Amyloidosis of the lung. Arch Pathol Lab Med 2017; 141 (02) 247-254
• 97 Ussavarungsi K, Yi ES, Maleszewski JJ. et al. Clinical relevance of pulmonary amyloidosis: an analysis of 76 autopsy-derived cases. Eur Respir J 2017; 49 (02) 10-13
• 98 Dubrey SW, Cha K, Anderson J. et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM 1998; 91 (02) 141-157
• 99 McCausland KL, White MK, Guthrie SD. et al. Light chain (AL) amyloidosis: The journey to diagnosis. Patient 2018; 11 (02) 207-216
• 100 Celli BR, Rubinow A, Cohen AS, Brody JS. Patterns of pulmonary involvement in systemic amyloidosis. Chest 1978; 74 (05) 543-547
• 101 Cordier JF, Loire R, Brune J. Amyloidosis of the lower respiratory tract. Clinical and pathologic features in a series of 21 patients. Chest 1986; 90 (06) 827-831
• 102 Gertz MA, Kyle RA, Thibodeau SN. Familial amyloidosis: a study of 52 North American-born patients examined during a 30-year period. Mayo Clin Proc 1992; 67 (05) 428-440
• 103 Utz JP, Swensen SJ, Gertz MA. Pulmonary amyloidosis. The Mayo Clinic experience from 1980 to 1993. Ann Intern Med 1996; 124 (04) 407-413
• 104 Capizzi SA, Betancourt E, Prakash UBS. Tracheobronchial amyloidosis. Mayo Clin Proc 2000; 75 (11) 1148-1152
• 105 Kyle RA, Bayrd ED. Amyloidosis: review of 236 cases. Medicine (Baltimore) 1975; 54 (04) 271-299
• 106 Ikeda S, Takabayashi Y, Maejima Y. et al. Nodular lung disease with five year survival and unilateral pleural effusion in AL amyloidosis. Amyloid 1999; 6 (04) 292-296
• 107 Berk JL, Keane J, Seldin DC. et al. Persistent pleural effusions in primary systemic amyloidosis: etiology and prognosis. Chest 2003; 124 (03) 969-977
• 108 Araoka T, Takeoka H, Nishioka K. et al. Successful management of refractory pleural effusion due to systemic immunoglobulin light chain amyloidosis by vincristine adriamycin dexamethasone chemotherapy: a case report. J Med Case Rep 2010; 4 (322) 322
• 109 Tada L, Anjum H, Linville WK, Surani S. Recurrent pleural effusions occurring in association with primary pulmonary amyloidosis. Case Rep Pulmonol 2015; 2015: 421201
• 110 Moy LN, Mirza M, Moskal B, Asado N, Shah B, Bitran J. Pulmonary AL amyloidosis: A review and update on treatment options. Ann Med Surg (Lond) 2022; 80 (May): 104060
• 111 Gustine JN, Staron A, Szalat RE. et al. Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: A 25-year longitudinal study. Am J Hematol 2022; 97 (09) 1189-1199
• 112 Kastritis E, Palladini G, Minnema MC. et al; ANDROMEDA Trial Investigators. Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N Engl J Med 2021; 385 (01) 46-58
• 113 Palladini G, Sachchithanantham S, Milani P. et al. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood 2015; 126 (05) 612-615
• 114 Kastritis E, Leleu X, Arnulf B. et al. Bortezomib, melphalan, and dexamethasone for light-chain amyloidosis. J Clin Oncol 2020; 38 (28) 3252-3260
• 115 Ehrlich MI, Hughes MS, Labadie BW. et al. Lung transplantation for pulmonary AL amyloidosis. Transplant Direct 2024; 10 (03) e1577
• 116 Kumar S, Dispenzieri A, Lacy MQ. et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 2012; 30 (09) 989-995
• 117 Lilleness B, Ruberg FL, Mussinelli R, Doros G, Sanchorawala V. Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis. Blood 2019; 133 (03) 215-223
• 118 Tomlinson R, Matigian N, Mollee P. Validation of the Boston University staging system in AL amyloidosis. Amyloid 2019; 26 (03) 125-127
• 119 Basset M, Milani P, Ferretti VV. et al. Prospective urinary albumin/creatinine ratio for diagnosis, staging, and organ response assessment in renal AL amyloidosis: results from a large cohort of patients. Clin Chem Lab Med 2022; 60 (03) 386-393
• 120 Şahan C, Cengiz K. Pulmonary amyloidosis in familial Mediterranean fever. Acta Clin Belg 2006; 61 (03) 147-151
• 121 Koksal D, Mutluay N, Bayiz H, Berktas B, Berkoglu M, Demirag F. Diffuse pulmonary amyloidosis due to familial Mediterranean fever, a rare presentation. Libyan J Med 2012; 7: 18482
• 122 Dias C, Tavares I, Magalhães A, Melo N. Pleural effusion in AA amyloidosis - A rare involvement of a rare disease. Rev Port Pneumol (2006) 2017; 23 (04) 234-236
• 123 Erdem H, Simşek I, Pay S, Dinc A, Deniz O, Ozcan A. Diffuse pulmonary amyloidosis that mimics interstitial lung disease in a patient with familial Mediterranean fever. J Clin Rheumatol 2006; 12 (01) 34-36
• 124 Takamori S, Yano H, Hayashi A. et al. Amyloid tumor in the anterior mediastinum: Report of a case. Surg Today 2004; 34 (06) 518-520
• 125 Calatayud J, Candelas G, Gómez A, Morado C, Trancho FH. Nodular pulmonary amyloidosis in a patient with rheumatoid arthritis. Clin Rheumatol 2007; 26 (10) 1797-1798
• 126 Fukatsu H, Miyoshi H, Ishiki K. Spontaneous resolution of multiple nodular pulmonary AA amyloidosis. Intern Med 2010; 49 (21) 2303-2307
• 127 Lachmann HJ, Goodman HJB, Gilbertson JA. et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007; 356 (23) 2361-2371
• 128 Hamer JPM, Janssen S, van Rijswijk MH, Lie KI. Amyloid cardiomyopathy in systemic non-hereditary amyloidosis. Clinical, echocardiographic and electrocardiographic findings in 30 patients with AA and 24 patients with AL amyloidosis. Eur Heart J 1992; 13 (05) 623-627
• 129 Shah KB, Inoue Y, Mehra MR. Amyloidosis and the heart: A comprehensive review. Arch Intern Med 2006; 166 (17) 1805-1813
• 130 Georgin-Lavialle S, Savey L, Buob D. et al; Collaborators. French practical guidelines for the diagnosis and management of AA amyloidosis. Rev Med Interne 2023; 44 (02) 62-71
• 131 van Gameren II, Hazenberg BPC, Bijzet J, van Rijswijk MH. Diagnostic accuracy of subcutaneous abdominal fat tissue aspiration for detecting systemic amyloidosis and its utility in clinical practice. Arthritis Rheum 2006; 54 (06) 2015-2021
• 132 Hazenberg BPC, Bijzet J, Limburg PC. et al. Diagnostic performance of amyloid A protein quantification in fat tissue of patients with clinical AA amyloidosis. Amyloid 2007; 14 (02) 133-140
• 133 Taylor MS, Sidiqi H, Hare J. et al. Current approaches to the diagnosis and management of amyloidosis. Intern Med J 2022; 52 (12) 2046-2067
• 134 Gottenberg JE, Merle-Vincent F, Bentaberry F. et al. Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: A followup report of tolerability and efficacy. Arthritis Rheum 2003; 48 (07) 2019-2024
• 135 Fernández-Nebro A, Olivé A, Castro MC. et al. Long-term TNF-α blockade in patients with amyloid A amyloidosis complicating rheumatic diseases. Am J Med 2010; 123 (05) 454-461
• 136 Okuda Y, Ohnishi M, Matoba K. et al. Comparison of the clinical utility of tocilizumab and anti-TNF therapy in AA amyloidosis complicating rheumatic diseases. Mod Rheumatol 2014; 24 (01) 137-143
• 137 Courties A, Grateau G, Philippe P. et al; Club Rhumatismes Inflammation and the REGATE Registry. AA amyloidosis treated with tocilizumab: case series and updated literature review. Amyloid 2015; 22 (02) 84-92
• 138 Ben-Zvi I, Kukuy O, Giat E. et al. Anakinra for colchicine-resistant familial Mediterranean fever: A randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol 2017; 69 (04) 854-862
• 139 Gillmore JD, Lovat LB, Persey MR, Pepys MB, Hawkins PN. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 2001; 358 (9275): 24-29
• 140 Lesser A. Ein fall von enchondroma osteiodes mixtum der lunge mit partieller amyloid entortung [in German]. Virchows Arch (Path Anat) 1877; 69: 404-408
• 141 Hamidi Asl K, Liepnieks JJ, Nakamura M, Benson MD. Organ-specific (localized) synthesis of Ig light chain amyloid. J Immunol 1999; 162 (09) 5556-5560
• 142 Lewis JE, Olsen KD, Kurtin PJ, Kyle RA. Laryngeal amyloidosis: a clinicopathologic and immunohistochemical review. Otolaryngol Head Neck Surg 1992; 106 (04) 372-377
• 143 Kourelis TV, Kyle RA, Dingli D. et al. Presentation and outcomes of localized immunoglobulin light chain amyloidosis: The Mayo Clinic experience. Mayo Clin Proc 2017; 92 (06) 908-917
• 144 Sakagiannis G, Giotakis E, Thompson LDR. Localized nasopharyngeal amyloidosis: A clinicopathologic series of 7 cases with a literature review. Head Neck Pathol 2018; 12 (04) 542-547
• 145 Send T, Spiegel JL, Schade G. et al. Amyloidosis of the upper aerodigestive tract: Management of a rare disease and review of the literature. Dysphagia 2019; 34 (02) 179-191
• 146 Galluzzi F, Garavello W. Surgical treatment of laryngeal amyloidosis: a systematic review. Eur Arch Otorhinolaryngol 2023; 280 (07) 3065-3074
• 147 Aydin O, Ustündağ E, Işeri M, Ozkarakaş H, Oğuz A. Laryngeal amyloidosis with laryngocele. J Laryngol Otol 1999; 113 (04) 361-363
• 148 Phillips NM, Matthews E, Altmann C, Agnew J, Burns H. Laryngeal amyloidosis: diagnosis, pathophysiology and management. J Laryngol Rhinol Otol 2017; 131 (S2): S41-S47
• 149 Pai KK, Omiunu AO, Llerena PA. et al. Localized laryngeal amyloidosis: A systematic review. Am J Otolaryngol 2022; 43 (05) 103550
• 150 Barnes Jr EL, Zafar T. Laryngeal amyloidosis: Clinicopathologic study of seven cases. Ann Otol Rhinol Laryngol 1977; 86 (6 Pt 1): 856-863
• 151 Pribitkin E, Friedman O, O'Hara B. et al. Amyloidosis of the upper aerodigestive tract. Laryngoscope 2003; 113 (12) 2095-2101
• 152 Wang Q, Chen H, Wang S. Laryngo-tracheobronchial amyloidosis: a case report and review of literature. Int J Clin Exp Pathol 2014; 7 (10) 7088-7093
• 153 Lanks CW, Van Natta TL, Hsia DW. Primary laryngotracheal amyloidosis with bilateral vocal cord involvement and associated bronchiectasis. J Bronchology Interv Pulmonol 2016; 23 (04) 347-349
• 154 Passerotti GH, Caniello M, Hachiya A, Santoro PP, Imamura R, Tsuji DH. Multiple-sited amyloidosis in the upper aerodigestive tract: Case report and literature review. Braz J Otorhinolaryngol 2008; 74 (03) 462-466
• 155 Carbone JE, Barker D, Stauffer JL. Sleep apnea in amyloidosis. Chest 1985; 87 (03) 401-403
• 156 Lesser BA, Leeper KVJ, Conway W. Amyloidosis treated with nasal obstructive sleep apnea in continuous positive airway pressure. Arch Intern Med 1988; 148: 2285-2287
• 157 Kiuru S, Nieminen T, Partinen M. Obstructive sleep apnoea syndrome in hereditary gelsolin-related amyloidosis. J Sleep Res 1999; 8 (02) 143-149
• 158 Siddachari RC, Chaukar DA, Pramesh CS, Naresh KN, de Souza CE, Dcruz AK. Laryngeal amyloidosis. J Otolaryngol 2005; 34 (01) 60-63
• 159 Deviprasad D, Pujary K, Balakrishnan R, Nayak DR. KTP laser in laryngeal amyloidosis: Five cases with review of literature. Indian J Otolaryngol Head Neck Surg 2013; 65 (Suppl. 01) 36-41
• 160 Chow LTC, Chow WH, Shum BS. Fatal massive upper respiratory tract haemorrhage: An unusual complication of localized amyloidosis of the larynx. J Laryngol Otol 1993; 107 (01) 51-53
• 161 Dermody SM, Campagnaro EL, Kupfer RA, Hogikyan ND, Morrison RJ. Laryngotracheobronchial amyloidosis: Patterns of presentation and management. Ann Otol Rhinol Laryngol 2022; 131 (07) 737-742
• 162 Tracy LF, Danis III DO, Rodriggs T, Kariveda R, Grillone GA. Laryngotracheal amyloidosis: Amyloid airway center 23-year experience. Laryngoscope 2024; 134 (04) 1606-1613
• 163 Neuner GA, Badros AA, Meyer TK, Nanaji NM, Regine WF. Complete resolution of laryngeal amyloidosis with radiation treatment. Head Neck 2012; 34 (05) 748-752
• 164 Hazenberg AJC, Hazenberg BPC, Dikkers FG. Long-term follow-up after surgery in localized laryngeal amyloidosis. Eur Arch Otorhinolaryngol 2016; 273 (09) 2613-2620
• 165 Ma L, Bandarchi B, Sasaki C, Levine S, Choi Y. Primary localized laryngeal amyloidosis: Report of 3 cases with long-term follow-up and review of the literature. Arch Pathol Lab Med 2005; 129 (02) 215-218
• 166 Crain MA, Lakhani DA, Balar AB, Hogg JP, Adelanwa A, Hailemichael E. Tracheobronchial amyloidosis: A case report and review of literature. Radiol Case Rep 2021; 16 (09) 2399-2403
• 167 Ding L, Li W, Wang K. et al. Primary tracheobronchial amyloidosis in China: Analysis of 64 cases and a review of literature. J Huazhong Univ Sci Technolog Med Sci 2010; 30 (05) 599-603
• 168 Smesseim I, Cobussen P, Thakrar R, Daniels H. Management of tracheobronchial amyloidosis: A review of the literature. ERJ Open Res 2024; 10 (01) 00540-02023
• 169 Saleiro S, Hespanhol V, Magalhães A. Endobronchial amyloidosis. J Bronchol. 2008; 15 (02) 95-99
• 170 Baqir M, Schwegman AR, Maldonado F, Johnson TF, Ryu JH. Airway amyloidosis: A retrospective analysis of 43 patients. J Bronchology Interv Pulmonol 2022; 29 (04) 275-282
• 171 Li D, Shi Z, Wang Y, Thakur A. Primary tracheobronchial amyloidosis: coronal CT scan may provide clues for early diagnosis. J Postgrad Med 2013; 59 (03) 223-225
• 172 O'Regan A, Fenlon HM, Beamis Jr JF, Steele MP, Skinner M, Berk JL. Tracheobronchial amyloidosis. The Boston University experience from 1984 to 1999. Medicine (Baltimore) 2000; 79 (02) 69-79
• 173 Pickford HA, Swensen SJ, Utz JP. Thoracic cross-sectional imaging of amyloidosis. AJR Am J Roentgenol 1997; 168 (02) 351-355
• 174 Marom EM, Goodman PC, McAdams HP. Diffuse abnormalities of the trachea and main bronchi. AJR Am J Roentgenol 2001; 176 (03) 713-717
• 175 Khan NA, Bhandari BS, Jyothula S, Ocazionez D, Buryanek J, Jani PP. Pulmonary manifestations of amyloidosis. Respir Med 2023; 219: 107426
• 176 Kirchner J, Jacobi V, Kardos P, Kollath J. CT findings in extensive tracheobronchial amyloidosis. Eur Radiol 1998; 8 (03) 352-354
• 177 Lawrence DA, Branson B, Oliva I, Rubinowitz A. The wonderful world of the windpipe: A review of central airway anatomy and pathology. Can Assoc Radiol J 2015; 66 (01) 30-43
• 178 Prince JS, Duhamel DR, Levin DL, Harrell JH, Friedman PJ. Nonneoplastic lesions of the tracheobronchial wall: Radiologic findings with bronchoscopic correlation. Radiographics 2002; 22 (Spec No): S215-S230
• 179 Chung JH, Kanne JP, Gilman MD. CT of diffuse tracheal diseases. AJR Am J Roentgenol 2011; 196 (03) W240-6
• 180 Takahashi N, Glockner J, Howe BM, Hartman RP, Kawashima A. Taxonomy and imaging manifestations of systemic amyloidosis. Radiol Clin North Am 2016; 54 (03) 597-612
• 181 Serraj M, Kamaoui I, Znati K. et al. Pseudotumoral tracheobronchial amyloidosis mimicking asthma: A case report. J Med Case Rep 2012; 6: 40
• 182 Tanrıverdi E, Özgül MA, Uzun O. et al. Tracheobronchial amyloidosis mimicking tracheal tumor. Case Rep Med 2016; 2016: 1084063
• 183 Brandelik SC, Heussel CP, Kauczor HU. et al. CT features in amyloidosis of the respiratory system - Comprehensive analysis in a tertiary referral center cohort. Eur J Radiol 2020; 129: 109123
• 184 Zhang LQ, Zhao YC, Wang XW, Yang J, Lu ZW, Cheng YS. Primary localized tracheobronchial amyloidosis presenting with massive hemoptysis: A case report and literature review. Clin Respir J 2017; 11 (01) 122-125
• 185 Arulanantham J, Officer C, O'Connor C. et al. Localized tracheobronchial amyloidosis: A rare case presentation and tailored management approaches. Respirol Case Rep 2021; 9 (09) e0820
• 186 Piazza C, Cavaliere S, Foccoli P, Toninelli C, Bolzoni A, Peretti G. Endoscopic management of laryngo-tracheobronchial amyloidosis: A series of 32 patients. Eur Arch Otorhinolaryngol 2003; 260 (07) 349-354
• 187 Neben-Wittich MA, Foote RL, Kalra S. External beam radiation therapy for tracheobronchial amyloidosis. Chest 2007; 132 (01) 262-267
• 188 Fiorelli A, Accardo M, Galluccio G, Santini M. Amiloidosis traqueobronquial tratada con resección con láser endobronquial y prótesis en Y autoexpansible [In Spanish]. Arch Bronconeumol 2013; 49 (07) 303-305
• 189 Firlinger I, Setinek U, Koller H. et al. A case of tracheobronchial amyloidosis treated with endoscopic debulking and external beam radiation therapy. Pneumologie 2013; 67 (07) 398-400
• 190 Morales A, Pari M, López-Lisbona R, Cubero N, Dorca J, Rosell A. Colchicine treatment for tracheobronchial amyloidosis. Respiration 2016; 91 (03) 251-255
• 191 Sommer P, Kumar G, Lipchik RJ, Patel JJ. Tracheobronchial amyloidosis managed with multimodality therapies. Ther Adv Respir Dis 2014; 8 (02) 48-52
• 192 Yan W, Li P, Wu C. et al. Case report: Management of primary tracheobronchial light chain amyloidosis in a patient with biclonal gammopathy using a systemic bortezomib-based regimen. Front Med (Lausanne) 2021; 8: 728561
• 193 Moore A, Kramer MR, Silvern D, Shtraichman O, Allen AM. Endobronchial brachytherapy-A novel approach for the management of airway amyloidosis. Brachytherapy 2018; 17 (06) 966-972
• 194 Monroe AT, Walia R, Zlotecki RA, Jantz MA. Tracheobronchial amyloidosis: a case report of successful treatment with external beam radiation therapy. Chest 2004; 125 (02) 784-789
• 195 Hui AN, Koss MN, Hochholzer L, Wehunt WD. Amyloidosis presenting in the lower respiratory tract. Clinicopathologic, radiologic, immunohistochemical, and histochemical studies on 48 cases. Arch Pathol Lab Med 1986; 110 (03) 212-218
• 196 Miyamoto T, Kobayashi T, Makiyama M. et al. Monoclonality of infiltrating plasma cells in primary pulmonary nodular amyloidosis: Detection with polymerase chain reaction. J Clin Pathol 1999; 52 (06) 464-467
• 197 Lim JK, Lacy MQ, Kurtin PJ, Kyle RA, Gertz MA. Pulmonary marginal zone lymphoma of MALT type as a cause of localised pulmonary amyloidosis. J Clin Pathol 2001; 54 (08) 642-646
• 198 Okuda M, Okuda Y, Ogura T. et al. Primary lung involvement with amyloid deposition in Waldenstöm's macroglobulinemia: Observations from over 20 years. Respirology 2004; 9 (03) 414-418
• 199 Grogg KL, Aubry MC, Vrana JA, Theis JD, Dogan A. Nodular pulmonary amyloidosis is characterized by localized immunoglobulin deposition and is frequently associated with an indolent B-cell lymphoproliferative disorder. Am J Surg Pathol 2013; 37 (03) 406-412
• 200 Kaplan B, Martin BM, Boykov O. et al. Co-deposition of amyloidogenic immunoglobulin light and heavy chains in localized pulmonary amyloidosis. Virchows Arch 2005; 447 (04) 756-761
• 201 Beer TW, Edwards CW. Pulmonary nodules due to reactive systemic amyloidosis (AA) in Crohn's disease. Thorax 1993; 48 (12) 1287-1288
• 202 Yang MC, Blutreich A, Das K. Nodular pulmonary amyloidosis with an unusual protein composition diagnosed by fine-needle aspiration biopsy: A case report. Diagn Cytopathol 2009; 37 (04) 286-289
• 203 Roden AC, Aubry MC, Zhang K. et al. Nodular senile pulmonary amyloidosis: a unique case confirmed by immunohistochemistry, mass spectrometry, and genetic study. Hum Pathol 2010; 41 (07) 1040-1045
• 204 Kobayashi H, Matsuoka R, Kitamura S, Tsunoda N, Saito K. Sjögren's syndrome with multiple bullae and pulmonary nodular amyloidosis. Chest 1988; 94 (02) 438-440
• 205 Lantuejoul S, Moulai N, Quetant S. et al. Unusual cystic presentation of pulmonary nodular amyloidosis associated with MALT-type lymphoma. Eur Respir J 2007; 30 (03) 589-592
• 206 Seguchi T, Kyoraku Y, Saita K. et al. Human T-cell lymphotropic virus type I (HTLV-1) associated myelopathy and Sjögren's syndrome representing pulmonary nodular amyloidosis and multiple bullae: Report of an autopsy case. Virchows Arch 2006; 448 (06) 874-876
• 207 Kinoshita Y, Ikeda T, Miyamura T. et al. Nodular pulmonary amyloidosis associated with Sjögren's syndrome. Intern Med 2022; 61 (06) 877-881
• 208 Weismann RE, Clagett OT, McDONALD JR. Amyloid disease of the lung treated by pneumonectomy; report of a case. J Thorac Surg 1947; 16 (03) 269-281
• 209 Schuller H, Bolin H, Linder E, Stenram U. Tumorforming amyloidosis of the lower respiratory system. Report of a case in the lung and a short review of the literature. Dis Chest 1962; 42 (01) 58-67
• 210 Oezkan F, Khan AM, Freitag L. et al. Hemoptysis in primary pulmonary amyloidoma treated with intrabronchial arterial coiling. Am J Respir Crit Care Med 2014; 190 (11) 1311-1314
• 211 Craver WL. Solitary amyloid tumor of the lung. A case report. J Thorac Cardiovasc Surg 1965; 49 (05) 860-867
• 212 Rubinow A, Celli BR, Cohen AS, Rigden BG, Brody JS. Localized amyloidosis of the lower respiratory tract. Am Rev Respir Dis 1978; 118 (03) 603-611
• 213 Lee SC, Johnson H. Multiple nodular pulmonary amyloidosis. A case report and comparison with diffuse alveolar-septal pulmonary amyloidosis. Thorax 1975; 30 (02) 178-185
• 214 Ayuso MC, Gilabert R, Bombi JA, Salvador A. CT appearance of localized pulmonary amyloidosis. J Comput Assist Tomogr 1987; 11 (01) 197-199
• 215 Gómez AT, Alonso RM, García MM, Fabbricatore AA, García-Tejedor JL. Thoracic amyloidosis: High-resolution computed tomographic findings in 3 cases. J Comput Assist Tomogr 2008; 32 (06) 926-928
• 216 Sachchithanantham S, Wechalekar AD. Imaging in systemic amyloidosis. Br Med Bull 2013; 107 (01) 41-56
• 217 Aylwin ACB, Gishen P, Copley SJ. Imaging appearance of thoracic amyloidosis. J Thorac Imaging 2005; 20 (01) 41-46
• 218 Czeyda-Pommersheim F, Hwang M, Chen SS, Strollo D, Fuhrman C, Bhalla S. Amyloidosis: Modern cross-sectional imaging. Radiographics 2015; 35 (05) 1381-1392
• 219 Authier FJ, Lechapt-Zalcman E, Mussini JM. et al. Marked systemic amyloid angiopathy in patients with Val107 transthyretin mutation. J Clin Neuromuscul Dis 1999; 1 (02) 82-85
• 220 Ueda M, Ando Y, Haraoka K. et al. Aging and transthyretin-related amyloidosis: Pathologic examinations in pulmonary amyloidosis. Amyloid 2006; 13 (01) 24-30
• 221 Abdulla J, Maltboek N, Birgens H. Localized diffuse pulmonary AL-amyloidosis. Ugeskr Laeger 1998; 160 (51) 7442-7444
• 222 Ohdama S, Akagawa S, Matsubara O, Yoshizawa Y. Primary diffuse alveolar septal amyloidosis with multiple cysts and calcification. Eur Respir J 1996; 9 (07) 1569-1571
• 223 Doshi A, Rodrigues M, Deshpande R, Udwadia Z. Spontaneous resolution of diffuse alveolar septal amyloidosis. Indian J Chest Dis Allied Sci 2001; 43 (03) 177-179
• 224 BoydKing A, Sharma O, Stevenson K. Localized interstitial pulmonary amyloid: a case report and review of the literature. Curr Opin Pulm Med 2009; 15 (05) 517-520
• 225 Kronen R, Ziehr DR, Kane AED, VanderLaan PA, Kholdani CA, Hallowell RW. Pulmonary amyloidosis as the presenting finding in a patient with multiple myeloma. Respir Med Case Rep 2022; 37: 101626
• 226 Ware LB, Keith FM, Gordon RL. et al. Lung transplantation for pulmonary amyloidosis: A case report. J Heart Lung Transplant 1998; 17 (11) 1129-1132
• 227 Ko HS, Davidson JW, Pruzanski W. Amyloid lymphadenopathy. Ann Intern Med 1976; 85 (06) 763-764
• 228 Urschel JD, Urschel DM. Mediastinal amyloidosis. Ann Thorac Surg 2000; 69 (03) 944-946
• 229 Fiorelli A, Accardo M, Ciancia G, Pettinato G, Santini M. Isolated mediastinal amyloidosis mimicking a neoplastic lesion. Gen Thorac Cardiovasc Surg 2014; 62 (05) 324-326
• 230 Fu J, Seldin DC, Berk JL. et al. Lymphadenopathy as a manifestation of amyloidosis: A case series. Amyloid 2014; 21 (04) 256-260
• 231 Thompson PJ, Jewkes J, Corrin B, Citron KM. Primary bronchopulmonary amyloid tumour with massive hilar lymphadenopathy. Thorax 1983; 38 (02) 153-154
• 232 Dalton HR, Featherstone T, Athanasou N. Organ limited amyloidosis with lymphadenopathy. Postgrad Med J 1992; 68 (795) 47-50
• 233 Gross BH. Radiographic manifestations of lymph node involvement in amyloidosis. Radiology 1981; 138 (01) 11-14
• 234 Matsuguma H, Suzuki H, Ishikawa Y. et al. Localized mediastinal lymph node amyloidosis showing an unusual unsynchronized pattern of enlargement and calcification on serial CT. Br J Radiol 2008; 81 (969) e228-e230
• 235 García Gallego F, Calleja Canelas JL. Letter: Hilar enlargement in amyloidosis. N Engl J Med 1974; 291 (10) 531
• 236 Zatloukal P, Bezdícek P, Schimonová M, Havlícek F, Tesarová P, Slováková A. Waldenström's macroglobulinemia with pulmonary amyloidosis. Respiration 1998; 65 (05) 414-416
• 237 Smith FB, Brown RB, Maguire G, Oliver J. Localized pleural microdeposition of type A amyloid in a patient with rheumatoid pleuritis. Histologic distinction from pleural involvement in systemic amyloidosis. Am J Clin Pathol 1993; 99 (03) 261-264
• 238 Yoshiya S, Maruyama R, Koga T, Shikada Y, Yano T, Maehara Y. Localized pleural amyloidosis: report of a case. Surg Today 2012; 42 (06) 597-600
• 239 Shimizu Y, Endou K, Hashizume Y. et al. Massive pleural effusion due to pleural AA amyloidosis. Am J Respir Crit Care Med 2012; 186 (12) e19-e20
• 240 Berk JL. Pleural effusions in systemic amyloidosis. Curr Opin Pulm Med 2005; 11 (04) 324-328
• 241 Pou C, Ferreiro L, Suárez-Antelo J. et al. Characteristics of pleural effusion due to amyloidosis. Ann Thorac Med 2023; 18 (02) 53-60
• 242 Coolbear F, Bilawich AM, Tongson J, Adamo J, Churg A. Pleural amyloidosis imitating pleural malignancy. Respir Med Case Rep 2017; 20: 195-197
• 243 Schwarz D, Jue C, Sikov W. Primary systemic amyloidosis and persistent pleural effusions. Amyloid 2009; 16 (04) 239-242
• 244 Charokopos A, Baqir M, Roden AC, Ryu JH, Moua T. Multifaceted pulmonary manifestations of amyloidosis: State-of-the-art update. Expert Rev Respir Med 2025; 19 (02) 107-120
• 245 Gertz MA, Cohen AD, Comenzo RL. et al. Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial. Blood 2023; 142 (14) 1208-1218
• 246 Maurer MS, Schwartz JH, Gundapaneni B. et al; ATTR-ACT Study Investigators. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 2018; 379 (11) 1007-1016
• 247 Gillmore JD, Judge DP, Cappelli F. et al; ATTRibute-CM Investigators. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N Engl J Med 2024; 390 (02) 132-142
• 248 Maurer MS, Kale P, Fontana M. et al; APOLLO-B Trial Investigators. Patisiran treatment in patients with transthyretin cardiac amyloidosis. N Engl J Med 2023; 389 (17) 1553-1565
• 249 Adams D, Gonzalez-Duarte A, O'Riordan WD. et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 2018; 379 (01) 11-21
• 250 Benson MD, Waddington-Cruz M, Berk JL. et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med 2018; 379 (01) 22-31
• 251 Judge DP, Kristen AV, Grogan M. et al. Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR). Cardiovasc Drugs Ther 2020; 34 (03) 357-370
• 252 Fontana M, Berk JL, Gillmore JD. et al; HELIOS-B Trial Investigators. Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. N Engl J Med 2025; 392 (01) 33-44
• 253 Tortosa-Cabañas M, Acosta Batlle J, Perna C, Bachiller-Corral J. Successful treatment of AA amyloidosis with tocilizumab, resulting in the disappearance of amyloid deposits: a case-based review. Egypt Rheumatol Rehabil 2024; 51 (01) 4-7